It’s the sort of verdict the size of which even John Grisham might think twice about including in one of his legal thrillers.
Johnson & Johnson was hit with an $8bn (£6.5bn) penalty by a real-life “runaway jury” over its marketing of an antipsychotic drug, Risperdal, which has the unfortunate potential side of effect of causing male users to develop breasts.
In Grisham’s bestselling book of that name – it focussed on tobacco litigation before Hollywood turned it into a movie about guns – his fictional good men and women baulked at an $800m award, ultimately settling for half that, opening the floodgates in the process.
Join our new commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies